158 related articles for article (PubMed ID: 16404221)
1. PET and TNM: evolution or revolution?
Cheow HK; Mikhaeel NG; O'Doherty MJ
Nucl Med Commun; 2006 Feb; 27(2):101-3. PubMed ID: 16404221
[No Abstract] [Full Text] [Related]
2. [18F]FLT-PET in oncology: current status and opportunities.
Been LB; Suurmeijer AJ; Cobben DC; Jager PL; Hoekstra HJ; Elsinga PH
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1659-72. PubMed ID: 15565331
[TBL] [Abstract][Full Text] [Related]
3. FDG PET/CT in oncology: "raising the bar".
Patel CN; Goldstone AR; Chowdhury FU; Scarsbrook AF
Clin Radiol; 2010 Jul; 65(7):522-35. PubMed ID: 20541652
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography: current status and future challenges.
Lin M; Shon IH; Lin P
Intern Med J; 2010 Jan; 40(1):19-29. PubMed ID: 20561362
[TBL] [Abstract][Full Text] [Related]
5. [IV. Hungarian PET/CT Multidisciplinary Consensus Conference -- position statement].
Katalin B; István S; Miklós K;
Magy Onkol; 2011 Jun; 55(2):117-27. PubMed ID: 21780330
[No Abstract] [Full Text] [Related]
6. [Quality control of PET imaging: from study to diagnosis].
Daisaki H
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2012; 68(7):916-25. PubMed ID: 22821167
[No Abstract] [Full Text] [Related]
7. Two decades at the cross-roads of biology, physics and epidemiology: lessons learned in [18F-]FDG positron emission tomography in oncology.
Rizvi SN; Comans EF; Boellaard R; van Tinteren H; Hoekstra OS
Eur J Cancer; 2010 Aug; 46(12):2150-8. PubMed ID: 20561780
[TBL] [Abstract][Full Text] [Related]
8. Clinical PET/CT imaging: promises and misconceptions.
Czernin J; Auerbach MA
Nuklearmedizin; 2005; 44 Suppl 1():S18-23. PubMed ID: 16395974
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
Larson SM; Schwartz LH
J Nucl Med; 2006 Jun; 47(6):901-3. PubMed ID: 16741296
[No Abstract] [Full Text] [Related]
10. To PET or not to PET: what are the indications?
Stroobants S
Eur J Cancer; 2011 Sep; 47 Suppl 3():S304-5. PubMed ID: 21943992
[No Abstract] [Full Text] [Related]
11. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose PET/CT in cancer imaging.
Kayani I; Groves AM
Clin Med (Lond); 2006; 6(3):240-4. PubMed ID: 16826854
[No Abstract] [Full Text] [Related]
13. What does PET imaging add to conventional staging of head and neck cancer patients?
Pohar S; Brown R; Newman N; Koniarczyk M; Hsu J; Feiglin D
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):383-7. PubMed ID: 17379443
[TBL] [Abstract][Full Text] [Related]
14. Invited commentary.
Spaggiari L; Casiraghi M; Guarize J
Ann Thorac Surg; 2013 Jan; 95(1):311. PubMed ID: 23272848
[No Abstract] [Full Text] [Related]
15. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
Landheer ML; Steffens MG; Klinkenbijl JH; Westenberg AH; Oyen WJ
Br J Surg; 2005 Nov; 92(11):1363-7. PubMed ID: 16187254
[TBL] [Abstract][Full Text] [Related]
16. When 18-fluorodeoxyglucose-positron emission tomography is indeterminate, the International Prognostic Index is the answer.
Martin P
Leuk Lymphoma; 2010 Apr; 51(4):569-70. PubMed ID: 20367180
[No Abstract] [Full Text] [Related]
17. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma.
Lodde M; Lacombe L; Friede J; Morin F; Saourine A; Fradet Y
BJU Int; 2010 Sep; 106(5):658-63. PubMed ID: 20151968
[TBL] [Abstract][Full Text] [Related]
18. [Technical Approaches for Quantitative Treatment Responses Using 18F-FDG PET].
Miwa K; Miyaji N; Umeda T; Murata T; Wagatsuma K; Sasaki M
Igaku Butsuri; 2015; 35(1):30-8. PubMed ID: 26753394
[TBL] [Abstract][Full Text] [Related]
19. Standards for PET image acquisition and quantitative data analysis.
Boellaard R
J Nucl Med; 2009 May; 50 Suppl 1():11S-20S. PubMed ID: 19380405
[TBL] [Abstract][Full Text] [Related]
20. The process for continuous improvement of the TNM classification.
Gospodarowicz MK; Miller D; Groome PA; Greene FL; Logan PA; Sobin LH
Cancer; 2004 Jan; 100(1):1-5. PubMed ID: 14692017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
